文献速递心力衰竭与心肌病心律失常冠心病

缺血性与非缺血性心肌病合并房颤患者的结局分析:GARFIELD-AF登记报告

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry.
PubMed 文献 · JAMA Cardiol · 2019-01-01

GARFIELD-AF前瞻性登记纳入11 738例新诊断房颤合并充血性心力衰竭患者,其中缺血性心肌病(ICM)占40.2%,非缺血性心肌病(NICM)占59.8%。ICM组口服抗凝药使用较少、单用抗血小板药较多,ACEI/ARB及β受体阻滞剂使用较多,且全因死亡、心血管死亡及大出血发生率均显著高于NICM组。

要点

  • ICM合并房颤患者口服抗凝药使用率低于NICM,单用抗血小板药更常见。
  • ICM组全因死亡10.2/100人年,NICM组7.0/100人年,差异显著。
  • ICM组心血管死亡5.1/100人年,NICM组2.9/100人年,大出血亦更高。

核心结论

  • ICM合并新诊断房颤患者较NICM患者口服抗凝药使用更少、单用抗血小板药更多,ACEI/ARB使用更多。
  • ICM组全因死亡、心血管死亡及大出血发生率均显著高于NICM组。

研究设计与样本

  • GARFIELD-AF为前瞻性、非干预性登记研究,2010年3月至2016年8月共纳入52 014例房颤患者。
  • 分析纳入11 738例年龄≥18岁、新诊断房颤(≤6周)且至少1项研究者确定的卒中危险因素患者。
  • 按心肌病病因分为ICM组4717例(40.2%)和NICM组7021例(59.8%),随访1年。

主要发现

  • 口服抗凝药(联合或不联合抗血小板药)使用:ICM组2753例(60.1%),NICM组5082例(73.7%)。
  • 单用抗血小板药:ICM组1576例(34.4%),NICM组1071例(15.5%)。
  • ACEI/ARB使用:ICM组72.6%(3439例),NICM组60.3%(4236例);β受体阻滞剂使用:ICM组63.3%(2988例),NICM组53.2%(3737例)。
  • 全因死亡每100人年:ICM组10.2(95%CI 9.2-11.1),NICM组7.0(95%CI 6.4-7.6);心血管死亡:ICM组5.1(95%CI 4.5-5.9),NICM组2.9(95%CI 2.5-3.4)。
  • 卒中/系统性栓塞每100人年:ICM组2.0(95%CI 1.6-2.5),NICM组1.5(95%CI 1.3-1.9);大出血:ICM组1.1(95%CI 0.8-1.4),NICM组0.7(95%CI 0.5-0.9)。

临床怎么用

  • 对房颤合并ICM患者应关注抗凝治疗不足及单用抗血小板药的倾向,评估卒中预防策略。
  • ICM合并房颤患者死亡及大出血风险较高,需加强风险分层与随访管理。

局限性

  • GARFIELD-AF为非干预性登记研究,治疗分组非随机,组间基线特征和用药不均衡可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Congestive heart failure (CHF) is commonly associated with nonvalvular atrial fibrillation (AF), and their combination may affect treatment strategies and outcomes. OBJECTIVE: To assess the treatment strategies and 1-year clinical outcomes of antithrombotic and CHF therapies for patients with newly diagnosed AF with concomitant CHF stratified by etiology (ischemic cardiomyopathy [ICM] vs nonischemic cardiomyopathy [NICM]). DESIGN, SETTING, AND PARTICIPANTS: The GARFIELD-AF registry is a prospective, noninterventional registry. A total of 52 014 patients with AF were enrolled between March 2010 and August 2016. A total of 11 738 patients 18 years and older with newly diagnosed AF (≤6 weeks' duration) and at least 1 investigator-determined stroke risk factor were included. Data were analyzed from December 2017 to September 2018. EXPOSURES: One-year follow-up rates of death, stroke/systemic embolism, and major bleeding were assessed. MAIN OUTCOMES AND MEASURES: Event rates per 100 person-years were estimated from the Poisson model and Cox hazard ratios (HRs) and 95% confidence intervals. RESULTS: The median age of the population was 71.0 years, 22 987 of 52 013 were women (44.2%) and 31 958 of 52 014 were white (61.4%). Of 11 738 patients with CHF, 4717 (40.2%) had ICM and 7021 (59.8%) had NICM. Prescription of oral anticoagulant and antiplatelet drugs was not balanced between groups. Oral anticoagulants with or without antiplatelet drugs were used in 2753 patients with ICM (60.1%) and 5082 patients with NICM (73.7%). Antiplatelets were prescribed alone in 1576 patients with ICM (34.4%) and 1071 patients with NICM (15.5%). Compared with patients with NICM, use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (72.6% [3439] vs 60.3% [4236]) and of β blockers (63.3% [2988] vs 53.2% [3737]) was higher in patients with ICM. Rates of all-cause and cardiovascular death per 100 patient-years were significantly higher in the ICM group (all-cause death: ICM, 10.2; 95% CI, 9.2-11.1; NICM, 7.0; 95% CI, 6.4-7.6; cardiovascular death: ICM, 5.1; 95% CI, 4.5-5.9; NICM, 2.9; 95% CI, 2.5-3.4). Stroke/systemic embolism rates tended to be higher in ICM groups compared with NICM groups (ICM, 2.0; 95% CI, 1.6-2.5; NICM, 1.5; 95% CI, 1.3-1.9). Major bleeding rates were significantly higher in the ICM group (1.1; 95% CI, 0.8-1.4) compared with the NICM group (0.7; 95% CI, 0.5-0.9). CONCLUSIONS AND RELEVANCE: Patients with ICM received oral anticoagulants with or without antiplatelet drugs less frequently and antiplatelets alone more frequently than patients with NICM, but they received angiotensin-converting enzyme inhibitors/angiotensin receptor blockers more often than patients with NICM. All-cause and cardiovascular death rates were higher in patients with ICM than patients with NICM. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01090362.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Corbalan R, Bassand JP, Illingworth L, et al. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry. JAMA Cardiol. 2019. PMID: 31066873. doi:10.1001/jamacardio.2018.4729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。